Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analysts give CRBP an average rating of "Moderate Buy" (2 sell, 7 buy, 2 strong buy) with an average 1‑year price target of $43.88, implying substantial upside versus the stock's recent open near $10.30.
• Corbus is a clinical‑stage biopharma advancing lenabasum (Phase‑3 for dcSSc); it reported Q1 EPS of ($1.25) beating estimates, has a market cap of about $183M, and institutional/hedge funds own roughly 64.6% of the shares.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given an average rating of "Moderate Buy" by the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $43.8750.

A number of equities analysts have recently commented on CRBP shares. Guggenheim initiated coverage on shares of Corbus Pharmaceuticals in a research note on Wednesday. They issued a "buy" rating and a $45.00 target price on the stock. Jefferies Financial Group upgraded Corbus Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, February 18th. Wall Street Zen raised Corbus Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research report on Saturday, April 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research note on Monday, April 20th. Finally, Oppenheimer upped their target price on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 10th.

Insider Buying and Selling

In related news, insider Dominic Smethurst sold 3,285 shares of the business's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $8.09, for a total value of $26,575.65. Following the transaction, the insider owned 95,887 shares in the company, valued at approximately $775,725.83. The trade was a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Velan Capital Investment Management LP grew its position in shares of Corbus Pharmaceuticals by 3.4% in the 3rd quarter. Velan Capital Investment Management LP now owns 61,000 shares of the biopharmaceutical company's stock worth $772,000 after acquiring an additional 2,000 shares in the last quarter. Mariner LLC raised its position in shares of Corbus Pharmaceuticals by 34.0% during the 3rd quarter. Mariner LLC now owns 20,840 shares of the biopharmaceutical company's stock valued at $264,000 after acquiring an additional 5,289 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Corbus Pharmaceuticals during the fourth quarter worth $54,000. ADAR1 Capital Management LLC bought a new position in Corbus Pharmaceuticals during the third quarter worth $129,000. Finally, Virtu Financial LLC acquired a new position in Corbus Pharmaceuticals in the fourth quarter worth $88,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

Corbus Pharmaceuticals Stock Up 4.3%

CRBP stock opened at $10.30 on Friday. The stock has a market capitalization of $182.72 million, a price-to-earnings ratio of -1.72 and a beta of 2.68. Corbus Pharmaceuticals has a 52-week low of $6.10 and a 52-week high of $20.56. The stock's fifty day simple moving average is $9.32 and its 200-day simple moving average is $10.06.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.78) by $0.53. As a group, analysts anticipate that Corbus Pharmaceuticals will post -4.78 earnings per share for the current fiscal year.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.